Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Capital Leases (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Capital Leases for 4 consecutive years, with $12000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Capital Leases changed N/A to $12000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $12000.0, a N/A change, with the full-year FY2023 number at $19000.0, changed N/A from a year prior.
  • Capital Leases was $12000.0 for Q3 2024 at Actinium Pharmaceuticals, down from $14000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $2.3 million in Q2 2022 to a low of $1000.0 in Q3 2022.
  • A 4-year average of $224545.5 and a median of $14000.0 in 2024 define the central range for Capital Leases.
  • Biggest YoY gain for Capital Leases was 11575.0% in 2022; the steepest drop was 95.35% in 2022.
  • Actinium Pharmaceuticals' Capital Leases stood at $3000.0 in 2021, then plummeted by 66.67% to $1000.0 in 2022, then surged by 1800.0% to $19000.0 in 2023, then crashed by 36.84% to $12000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Capital Leases are $12000.0 (Q3 2024), $14000.0 (Q2 2024), and $17000.0 (Q1 2024).